Penrose TherapeuTx Appoints Pharmaceutical Leader David Sherris, Ph.D., as President and Chief Executive Officer
Penrose TherapeuTx, a privately held clinical stage small molecule drug development company committed to improving patient lives through innovative oncology therapies, today announced the appointment of David Sherris, Ph.D. as President and Chief Executive Officer.
- Penrose TherapeuTx, a privately held clinical stage small molecule drug development company committed to improving patient lives through innovative oncology therapies, today announced the appointment of David Sherris, Ph.D. as President and Chief Executive Officer.
- A first-in-class, small molecule drug technology attacking tumor cells leading to their necrotic death is an exciting and novel means to tackle cancer, said Dr. Sherris, Chief Executive Officer and President of Penrose TherapeuTx.
- Prior to Penrose TherapeuTx, Dr. Sherris was President and Chief Executive Officer of GenAdam Therapeutics, Paloma Pharmaceuticals and VasculoMedics, private biotech companies.
- Penrose TherapeuTx is a U.S.-based pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers.